NeuroPace FY2025 EPS Estimate Raised by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has raised its FY2025 earnings estimate for NeuroPace, projecting a loss of ($0.83) per share, improved from the earlier estimate of ($0.87).
• NeuroPace reported quarterly earnings of ($0.26) per share, missing analyst estimates, but exceeded revenue expectations with $23.52 million in revenue.
• NeuroPace maintains a consensus rating of "Buy" from analysts, with target prices ranging from $15.00 to $18.00 following various research reports.

NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Investment analysts at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for NeuroPace in a report released on Wednesday, August 13th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will earn ($0.83) per share for the year, up from their previous forecast of ($0.87). Cantor Fitzgerald currently has a "Overweight" rating and a $17.00 target price on the stock. The consensus estimate for NeuroPace's current full-year earnings is ($1.00) per share.

NeuroPace (NASDAQ:NPCE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The firm had revenue of $23.52 million for the quarter, compared to analyst estimates of $23.08 million. NeuroPace had a negative return on equity of 168.61% and a negative net margin of 29.29%. NeuroPace has set its FY 2025 guidance at EPS.

Several other research firms have also recently weighed in on NPCE. JPMorgan Chase & Co. upped their price objective on NeuroPace from $14.00 to $16.00 and gave the stock an "overweight" rating in a research report on Wednesday, May 14th. HC Wainwright initiated coverage on NeuroPace in a report on Wednesday, May 28th. They set a "buy" rating and a $18.00 target price on the stock. Wells Fargo & Company dropped their price objective on NeuroPace from $17.00 to $15.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 13th. Finally, Zacks Research lowered NeuroPace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 13th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $16.60.

NeuroPace Stock Up 5.0%

Shares of NPCE stock traded up $0.41 on Friday, hitting $8.66. 506,717 shares of the stock were exchanged, compared to its average volume of 276,521. The company has a current ratio of 5.47, a quick ratio of 4.51 and a debt-to-equity ratio of 3.02. The firm has a market capitalization of $286.48 million, a P/E ratio of -10.31 and a beta of 1.89. The business has a 50-day moving average of $9.72 and a 200 day moving average of $11.64. NeuroPace has a fifty-two week low of $5.45 and a fifty-two week high of $18.98.

Hedge Funds Weigh In On NeuroPace

A number of large investors have recently made changes to their positions in NPCE. JPMorgan Chase & Co. increased its stake in shares of NeuroPace by 440.4% during the fourth quarter. JPMorgan Chase & Co. now owns 64,826 shares of the company's stock worth $725,000 after purchasing an additional 52,829 shares during the period. Geode Capital Management LLC increased its stake in shares of NeuroPace by 1.8% during the fourth quarter. Geode Capital Management LLC now owns 322,973 shares of the company's stock worth $3,615,000 after purchasing an additional 5,781 shares during the period. Wells Fargo & Company MN grew its position in NeuroPace by 54.2% during the fourth quarter. Wells Fargo & Company MN now owns 6,483 shares of the company's stock worth $73,000 after buying an additional 2,279 shares in the last quarter. Barclays PLC grew its position in NeuroPace by 33.8% during the fourth quarter. Barclays PLC now owns 27,609 shares of the company's stock worth $309,000 after buying an additional 6,976 shares in the last quarter. Finally, Walleye Capital LLC acquired a new stake in NeuroPace during the fourth quarter worth approximately $319,000. Institutional investors own 78.83% of the company's stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.